Parantu Shah
Overview
Explore the profile of Parantu Shah including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
854
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
DAngelo S, Lebbe C, Nghiem P, Brohl A, Mrowiec T, Leslie T, et al.
Clin Cancer Res
. 2024 Jul;
30(19):4352-4362.
PMID: 39047170
Purpose: Avelumab (anti-PD-L1) became the first approved treatment for metastatic Merkel cell carcinoma (mMCC) based on results from the phase II JAVELIN Merkel 200 trial. In this study, we report...
2.
Manitz J, Gerhold-Ay A, Kieslich P, Shah P, Mrowiec T, Tyroller K
Cancer Med
. 2024 Jun;
13(12):e7411.
PMID: 38924353
Background: Avelumab first-line (1 L) maintenance is a standard of care for advanced urothelial carcinoma (aUC) based on the JAVELIN Bladder 100 phase 3 trial, which showed that avelumab 1 ...
3.
Naranbhai V, Viard M, Dean M, Groha S, Braun D, Labaki C, et al.
Lancet Oncol
. 2021 Dec;
23(1):172-184.
PMID: 34895481
Background: Predictive biomarkers could allow more precise use of immune checkpoint inhibitors (ICIs) in treating advanced cancers. Given the central role of HLA molecules in immunity, variation at the HLA...
4.
DAngelo S, Lebbe C, Mortier L, Brohl A, Fazio N, Grob J, et al.
J Immunother Cancer
. 2021 Jul;
9(7).
PMID: 34301810
Background: Avelumab (anti-programmed death ligand 1 (PD-L1)) is approved in multiple countries for the treatment of metastatic Merkel cell carcinoma (mMCC), a rare and aggressive skin cancer. We report efficacy...
5.
DAngelo S, Bhatia S, Brohl A, Hamid O, Mehnert J, Terheyden P, et al.
J Immunother Cancer
. 2020 May;
8(1).
PMID: 32414862
Background: Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with a high risk of metastasis. In 2017, avelumab (anti-programmed death-ligand 1 (PD-L1)) became the first approved treatment...
6.
Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al.
Nat Rev Drug Discov
. 2019 Apr;
18(6):463-477.
PMID: 30976107
Drug discovery and development pipelines are long, complex and depend on numerous factors. Machine learning (ML) approaches provide a set of tools that can improve discovery and decision making for...
7.
Pettazzoni P, Viale A, Shah P, Carugo A, Ying H, Wang H, et al.
Cancer Res
. 2015 Mar;
75(6):1091-101.
PMID: 25736685
Mutated KRAS (KRAS*) is a fundamental driver in the majority of pancreatic ductal adenocarcinomas (PDAC). Using an inducible mouse model of KRAS*-driven PDAC, we compared KRAS* genetic extinction with pharmacologic...
8.
Muller A, Schackert H, Lange B, Ruschoff J, Fuzesi L, Willert J, et al.
Am J Med Genet A
. 2005 Dec;
140(3):195-9.
PMID: 16372347
Hereditary non-polyposis colorectal cancer (HNPCC) syndrome is caused by heterozygous germline mutations in DNA mismatch repair genes (MMR), (MSH2, MLH1, MSH6, and PMS2) and it is inherited in an autosomal...